Members of APCaRI are involved in a wide range of translational, clinical and discovery research events such as scientific conferences and meetings. These meetings help keep us at the forefront of scientific discovery and application. Our scientists and trainees present posters and give talks helping stimulate interest in the overall program by national and international collaborations
We are also invested in the local and provincial community, reaching out to Albertans through many events tied to fundraising and prostate cancer awareness. We work alongside organizations like the Alberta Cancer foundation, Prostate Cancer Canada, MotorCycle Ride for Dad and Movember to help stimulate fundraising as well as provide the donors with a direct link and people to answer questions about where their donated dollars actually go.
The staff at the Alberta Cancer Foundation have harnessed our group for many events since we have arrived in Alberta.
APCaRI 2018 Fall Symposium
On Oct. 26-27, 2018, APCaRI will celebrate its 11th research meeting at the Banff Park Lodge, Alberta.
Over 60 participants including clinicians, scientists, clinical research personnel, trainees, benefactors and representatives of PCa support groups will participate in this fun and enriching event.
The team will benefit from the insight and experience that will be shared by national and international keynote speakers.
Generously supported by the Bird Dogs and the Alberta Cancer Foundation
Why did the chicken cross the road…?
Konstantin Stoletov and Lian Willetts co-first-authored an article published recently in Nature Communications titled “Quantitative in vivo whole genome motility screen reveals novel therapeutic targets to block cancer metastasis“. These two researchers, along with fellow Lewis lab members and collaborators from the University of Calgary and Vanderbilt University set out to determine what genes and signaling networks are involved in the rate-limiting steps of solid tumour cell motility, in vivo. But the team was hampered by the lack of an effective, quantitative, in vivo imaging platform. They wanted to visualize the movement of tumour cells, or lack of, in real-time AND use this intravital imaging platform to screen a large bank of tumour cells harboring single gene mutations for cells that show a loss of motility.
When tumour cells metastasize they get into (intravasate) the hosts’ bloodstream and use the vascular system like roadways to travel throughout the body. This lets the tumour cells colonize new microenvironments where they will proliferate and form new tumours. So metastatis is really dependent on tumour cell motility. Although there are many different types of solid tumours known, previous research suggests that if the tumour cells can mobilize and metastasize then the expressed motility-related genes share homology across tumour types. This is great news because it would mean that therapeutic targets aimed at stopping motility could also stop metastasis for many tumour types!
The Lewis lab researchers and their collaborators developed an in vivo, fluorescent, time-lapse screening platform that uses shell-less avian embryos for tumour growth and formation. The avian embryo is an excellent tumour model because the tumour cells will grow on the chorioallantoic membrane in a single cell layer, making in vivo cell motility imaging actually doable.
Using this platform the team screened over 30 000 human genes for the ones needed for cell motility and ultimately found 17 genes that looked to be effective metastasis-blocking gene targets. Stoletov, along with other Lewis lab members, are continuing this research by studying these 17 attractive candidates further to determine which one (s) would make therapeutic metastasis-blocking targets.
This article has generated a lot of interest in the scientific community and in the general public! Check out the links below to mentions and articles in the media.